CN105263923B - 嘧啶化合物及它们作为γ分泌酶调节剂的用途 - Google Patents

嘧啶化合物及它们作为γ分泌酶调节剂的用途 Download PDF

Info

Publication number
CN105263923B
CN105263923B CN201480032083.0A CN201480032083A CN105263923B CN 105263923 B CN105263923 B CN 105263923B CN 201480032083 A CN201480032083 A CN 201480032083A CN 105263923 B CN105263923 B CN 105263923B
Authority
CN
China
Prior art keywords
methyl
pyrimidine
groups
phenyl
imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480032083.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105263923A (zh
Inventor
Y.贝西德斯基
U.英格夫
K.保尔森
C.林德
I.麦克萨里
J.马姆博格
A.帕普奇克海因
P.阿维森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acturum Life Science AB
Original Assignee
Acturum Life Science AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acturum Life Science AB filed Critical Acturum Life Science AB
Publication of CN105263923A publication Critical patent/CN105263923A/zh
Application granted granted Critical
Publication of CN105263923B publication Critical patent/CN105263923B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480032083.0A 2013-06-04 2014-06-03 嘧啶化合物及它们作为γ分泌酶调节剂的用途 Expired - Fee Related CN105263923B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350685-2 2013-06-04
SE1350685 2013-06-04
PCT/EP2014/061503 WO2014195323A1 (en) 2013-06-04 2014-06-03 Pyrimidine compounds and their use as gamma secretase modulators

Publications (2)

Publication Number Publication Date
CN105263923A CN105263923A (zh) 2016-01-20
CN105263923B true CN105263923B (zh) 2017-06-23

Family

ID=50877325

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480032083.0A Expired - Fee Related CN105263923B (zh) 2013-06-04 2014-06-03 嘧啶化合物及它们作为γ分泌酶调节剂的用途

Country Status (9)

Country Link
US (1) US9439904B2 (https=)
EP (1) EP3004079B1 (https=)
JP (1) JP6368777B2 (https=)
CN (1) CN105263923B (https=)
DK (1) DK3004079T3 (https=)
ES (1) ES2665421T3 (https=)
NO (1) NO3004079T3 (https=)
PL (1) PL3004079T3 (https=)
WO (1) WO2014195323A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3481829B1 (en) * 2016-07-08 2021-04-07 H. Hoffnabb-La Roche Ag Fused pyrimidine derivatives
CN108191776A (zh) * 2018-01-22 2018-06-22 无锡富泽药业有限公司 一种尿嘧啶的绿色生产工艺
WO2020247707A1 (en) * 2019-06-05 2020-12-10 Chunyu Wang SYSTEMS AND METHOD FOR INHIBITING γ-SECRETASE PRODUCTION OF AMYLOID-β PEPTIDES
US12297244B2 (en) 2019-06-05 2025-05-13 Rensselaer Polytechnic Institute Systems and methods for inhibiting γ-secretase production of amyloid-β peptides
CN110372603A (zh) * 2019-06-24 2019-10-25 南京普锐达医药科技有限公司 一种2-氯-5-氟-6-乙基嘧啶的合成方法
CN113149977A (zh) 2020-01-22 2021-07-23 苏州爱科百发生物医药技术有限公司 一类呼吸道合胞病毒抑制剂的合成与用途
CA3214360A1 (en) 2021-03-23 2022-09-29 Halia Therapeutics, Inc. Pyrimidine derivatives useful as lrrk2 kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025780A1 (en) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
WO2007053452A1 (en) * 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2009103652A1 (en) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030312A1 (it) 2003-02-21 2004-08-22 Chiesi Farma Spa Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer.
US20080153817A1 (en) 2003-08-07 2008-06-26 Dirk Beher Treatment for Alzheimer's Disease and Related Conditions
DE602004023762D1 (de) 2003-12-03 2009-12-03 Merck Sharp & Dohme Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
MY149038A (en) * 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
WO2007125364A1 (en) 2006-04-26 2007-11-08 Merck Sharp & Dohme Limited Piperidines and related compounds for treatment of alzheimer’s disease
KR20090018963A (ko) 2006-05-19 2009-02-24 에자이 알앤드디 매니지먼트 가부시키가이샤 우레아계 신나미드 유도체
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
EP2120573A4 (en) 2007-02-12 2011-05-25 Merck Sharp & Dohme piperidine
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2166854A4 (en) 2007-06-13 2012-05-16 Merck Sharp & Dohme TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
MX2010001506A (es) 2007-08-06 2010-03-10 Schering Corp Moduladores de gamma secretasa.
ES2375919T3 (es) 2008-01-11 2012-03-07 F. Hoffmann-La Roche Ag Moduladores de beta-amiloide.
ES2429517T3 (es) * 2008-10-09 2013-11-15 F. Hoffmann-La Roche Ag Moduladores para la beta amiloide
CA2742897A1 (en) 2008-11-06 2010-05-14 Astrazeneca Ab Modulators of amyloid beta.
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
UY32622A (es) 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
JP2012532912A (ja) 2009-07-15 2012-12-20 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
BR112012017310A2 (pt) 2010-01-15 2016-04-19 Janssen Pharmaceuticals Inc derivados de triazol substituídos como moduladores de gama secretase
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025780A1 (en) * 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
WO2007053452A1 (en) * 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
WO2009103652A1 (en) * 2008-02-22 2009-08-27 F. Hoffmann-La Roche Ag Modulators for amyloid beta

Also Published As

Publication number Publication date
NO3004079T3 (https=) 2018-06-16
PL3004079T3 (pl) 2018-07-31
US9439904B2 (en) 2016-09-13
EP3004079A1 (en) 2016-04-13
US20160129002A1 (en) 2016-05-12
JP6368777B2 (ja) 2018-08-01
JP2016520637A (ja) 2016-07-14
WO2014195323A1 (en) 2014-12-11
DK3004079T3 (en) 2018-04-16
CN105263923A (zh) 2016-01-20
ES2665421T3 (es) 2018-04-25
EP3004079B1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
CN105263923B (zh) 嘧啶化合物及它们作为γ分泌酶调节剂的用途
CN110300589B (zh) 作为cftr增效剂的双环异杂芳基衍生物
TWI634112B (zh) Ｃｏｔ調節劑及其使用方法
CN106008340B (zh) 稠环衍生物、其制备方法、中间体、药物组合物及应用
CN106211770B (zh) 作为γ‑分泌酶调节剂的色烯和1,1A,2,7B‑四氢环丙烷并[c]色烯吡啶并吡嗪二酮
CN114728975A (zh) 唑稠合的哒嗪-3(2h)-酮衍生物
CN115850268A (zh) 作为cftr增效剂的吡咯并嘧啶
CN108026067B (zh) 作为cot调节剂的6-氨基-喹啉-3-腈
CN110267945A (zh) 氰基取代的吲哚化合物及其作为lsd1抑制剂的用途
CN105683181A (zh) 新的氨基嘧啶衍生物
CN108026050A (zh) 作为RORγ调节剂的新型化合物
KR20130133905A (ko) 트로포미오신-관련 키나제의 억제제인 피롤로[2,3-d]피리미딘 유도체
AU2019209475A1 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP2019507766A (ja) 線維症の治療のための新規化合物及びその医薬組成物
CN105308037B (zh) 三唑化合物及其作为γ分泌酶调节剂的用途
CN105408321A (zh) 新的吲哚和吡咯衍生物、它们的制备方法和含有它们的药物组合物
KR20110091550A (ko) 5-ｈｔ2ｂ 수용체 길항활성을 가지는 신규 피라졸-3-카복사미드 유도체
CN107074805A (zh) 用于治疗疾病的gls1抑制剂
TW201546060A (zh) 肌旋蛋白相關（ｔｒｏｐｏｍｙｏｓｉｎ－ｒｅｌａｔｅｄ）之激酶抑制劑
TW201731511A (zh) １，３，４-噻二唑化合物及其在治療癌症中之用途
CN108884093A (zh) 6,7,8,9-四氢-5H-吡啶并[2,3-d]氮杂*多巴胺D3配体
CN105263922B (zh) 三唑化合物及其作为γ分泌酶调节剂的用途
CN103261193A (zh) 抑制白三烯生成的*二唑抑制剂
CN108463462B (zh) 苯二氮䓬类作为溴结构域抑制剂
JP2008501775A (ja) オキシトシン拮抗剤としての置換トリアゾール誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170623

Termination date: 20210603